A New Front in Cancer Research: Amplia's High Stakes Gamble Amplia Therapeutics' collaboration with Eli Lilly & Company is a significant step forward in cancer research, potentially disrupting the lucrative non small cell lung cancer (NSCLC) market.
Beneath this partnership lies a complex web of scientific theory and clinical trial risks.
At its core, Amplia's investigational FAK blocker narmafotinib is being paired with Eli Lilly's KRAS G12C inhibitor olomorasib to overcome resistance to the latter.